Efficacy of Combined Aromatase Inhibitor and Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Metastatic Breast Cancer
Journal of Breast Disease
;
(2): 46-51, 2018.
Article
in English
| WPRIM
| ID: wpr-718904
ABSTRACT
PURPOSE:
Endocrine therapy is the preferred treatment for hormone receptor (HR)-positive metastatic breast cancer (MBC). We investigated the efficacy of combined aromatase inhibitor (AI) and luteinizing hormone-releasing hormone (LHRH) agonist in premenopausal patients with HR-positive MBC.METHODS:
We retrospectively analyzed the medical records of 21 HR-positive premenopausal MBC patients treated with combined AI and LHRH agonist therapy.RESULTS:
The median follow-up period was 32.9 months. The overall response rate was 47.6%, with three complete responses (14.3%) and seven partial responses (33.3%). Nine patients (42.9%) achieved stable disease lasting more than 6 months; thus, the clinical benefit rate was 90.4%. The median time to progression was 45.4 months. No patients experienced grade 3 or 4 toxicity.CONCLUSION:
Combined AI and LHRH agonist treatment safely and effectively induced remission or prolonged disease stabilization, suggesting that this could be a promising treatment option for HR-positive premenopausal patients with MBC.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Lutein
/
Breast
/
Breast Neoplasms
/
Aromatase
/
Medical Records
/
Retrospective Studies
/
Follow-Up Studies
/
Gonadotropin-Releasing Hormone
/
Goserelin
/
Premenopause
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Journal of Breast Disease
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS